Docket No.: S1509.70037US01

IN THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims. Additions are indicated by underlining and deletions are indicated by strikeouts and/or double bracketing.

- 1. (Cancelled)
- 2. (Previously presented) The method of claim 4, wherein the sagging is determined using viscoelasticity.
- 3. (Previously presented) The method of claim 4, wherein the delivery vehicle is a cream.
- 4. (Previously presented) A method, comprising an act of:

rubbing a delivery vehicle comprising L-arginine into a breast for a period of time sufficient to reduce sagging, wherein the delivery vehicle comprises a hostile biophysical environment containing a penetrating agent, the penetrating agent comprising an ionic salt present at at least 5% weight by volume.

- 5-6. (Cancelled)
- 7. (Previously presented) The method of claim 4, wherein the effective concentration of Larginine is at least 5% by weight/volume of the delivery vehicle.
- 8. (Previously presented) The method of claim 4, wherein the delivery vehicle further comprises one or more of water, mineral oil, glyceryl stereate, squalene, propylene glycol stearate, wheat germ oil, glyceryl stearate, isopropyl myristate, steryl stearate, polysorbate 60, propylene glycol, oleic acid, tocopherol acetate, collagen, sorbitan stearate, vitamin A, vitamin D, triethanolamine, methylparaben, aloe vera extract, imidazolidinyl urea, propylparaben, PND, or BHA.

Docket No.: S1509.70037US01

9. (Previously presented) The method of claim 4, further comprising an act of reapplying the delivery vehicle to the breast.

3

- 10. (Previously presented) The method of claim 9, comprising repeating the act of reapplying the delivery vehicle to the breast between 2 and 30 times, inclusively, within a time period of about 30 days.
- 11. (Cancelled)
- 12. (Currently amended) The method of claim 4, wherein the penetrating agent is present in the delivery vehicle at a concentration at least sufficient to allow the nitric oxide donor L-arginine to act for at least about 3 hours.
- 13. (Cancelled)
- 14. (Previously presented) The method of claim 4, wherein the ionic salt comprises one or more of lithium chloride, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, or choline chloride.
- 15. (Previously presented) The method of claim 4, wherein the ionic salt is present at a concentration of at least about 10% by weight.
- 16-19. (Cancelled)
- 20. (Previously presented) A method, comprising an act of:
 - rubbing a delivery vehicle into a breast, the delivery vehicle containing L-arginine for a period of time sufficient to allow the breast to absorb a sufficient quantity of L-arginine to produce a smoother surface in the breast, wherein the delivery vehicle comprises a hostile

biophysical environment containing a penetrating agent, the penetrating agent comprising an ionic salt present at at least 5% weight by volume.

4

- 21. (Previously presented) The method of claim 20, wherein the delivery vehicle comprises one or more of water, mineral oil, glyceryl stereate, squalene, propylene glycol stearate, wheat germ oil, glyceryl stearate, isopropyl myristate, steryl stearate, polysorbate 60, propylene glycol, oleic acid, tocopherol acetate, collagen, sorbitan stearate, vitamin A, vitamin D, triethanolamine, methylparaben, aloe vera extract, imidazolidinyl urea, propylparaben, PND, or BHA.
- 22. (Previously presented) The method of claim 20, further comprising an act of reapplying the delivery vehicle to the breast.
- 23. (Previously presented) The method of claim 22, comprising repeating the act of reapplying the delivery vehicle to the breast after between about 8 hours and about 48 hours after the act of applying the delivery vehicle.

24-26. (Cancelled)

- 27. (Previously presented) The method of claim 20, wherein the ionic salt comprises one or more of lithium chloride, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, or choline chloride.
- 28. (Previously presented) The method of claim 20, wherein the ionic salt is present at a concentration of at least about 10% by weight.
- 29. (Previously presented) A method, comprising:

administering, to a subject diagnosed as having breast ptosis, a composition comprising L-arginine by rubbing the composition into a breast of the subject, the

composition further comprising a hostile biophysical environment containing a penetrating agent, the penetrating agent comprising an ionic salt present at at least 5% weight by volume.

5

30. (New) The method of claim 20, wherein the delivery vehicle is a cream.